Rat Spinal Cord α2‐Adrenoceptors are of the α2A‐Subtype: Comparison with α2A‐ and α2B‐Adrenoceptors in Rat Spleen, Cerebral Cortex and Kidney Using 3H‐RX821002 Ligand Binding

Binding of the alpha 2-adrenoceptor antagonist radioligand 3H-RX821002 was investigated in membranes from rat spinal cord, spleen, cerebral cortex and kidney. The ligand was found to bind to saturable binding sites with apparent uniform affinities within each tissue. Seven compounds, some of which have previously been reported to be selective for either alpha 2A- or alpha 2B-adrenoceptors, were used in competition with 3H-RX821002. By using computer modelling, competition curves generated for three of these compounds (ARC 239, prazosin and oxymetazoline) could be resolved into two site fits in the kidney, Kd's of the drugs being compatible with the notion that these sites corresponded to alpha 2A- and alpha 2B-adrenoceptors. Moreover, rauwolscine and yohimbine were found to be about 14 and 9-fold selective for alpha 2B-adrenoceptors in the kidney. In all other tissues studied drug competition curves were uniphasic and computer modelled into one site fits, drug Kd's being well correlated to those for the alpha 2A-adrenoceptor. In rat spinal cord 26 further drugs, which showed wide variation in structure, were evaluated in competition with 3H-RX821002. Of these compounds, competion curves of the agonists UK-14,304, (-) and (+) adrenaline were modelled into two site fits whereas those of the remaining compounds could be modelled only into one site fits. Since the high affinity site for UK-14,304, (-) and (+) adrenaline was eliminated when EDTA, Gpp(NH)p and 140 mM NaCl was present in the assay the heterogeniety observed in spinal cord was considered to be due to formation of high and low affinity conformations of the alpha 2-adrenoceptor for agonists. It is concluded that 3H-RX821002 is useful to label both alpha 2A- and alpha 2B-adrenoceptors in the rat. Moreover, the binding sites labelled by 3H-RX821002 in the spinal cord appear to consist of a single population of alpha 2-adrenoceptors of the alpha 2A-type.

[1]  J. Wikberg,et al.  Antinociceptive Actions of α2‐Adrenoceptor Agonists in the Rat Spinal Cord: Evidence for Antinociceptive α2‐Adrenoceptor Subtypes and Dissociation of Antinociceptive α2‐Adrenoceptors from Cyclic AMP , 1990 .

[2]  Y. V. van Megen,et al.  Alpha 2-adrenoceptors in homogenates of rat nasal mucosa. , 1990, European journal of pharmacology.

[3]  M. Caron,et al.  Expansion of the alpha 2-adrenergic receptor family: cloning and characterization of a human alpha 2-adrenergic receptor subtype, the gene for which is located on chromosome 2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Wikberg,et al.  Further Characterization of the Guinea Pig Cerebral Cortex Idazoxan Receptor: Solubilization, Distinction from the Imidazole Site, and Demonstration of Cirazoline as an Idazoxan Receptor‐Selective Drug , 1990, Journal of neurochemistry.

[5]  D. Langin,et al.  Binding of [3H]idazoxan and of its methoxy derivative [3H] RX821002 in human fat cells: [3H]idazoxan but not [3H] RX821002 labels additional non-alpha 2-adrenergic binding sites. , 1990, Molecular pharmacology.

[6]  G. Gebhart,et al.  Antinociceptive effects of intrathecal adrenoceptor agonists in a rat model of visceral nociception. , 1990, The Journal of pharmacology and experimental therapeutics.

[7]  A. Tucker,et al.  Molecular characterization of a rat alpha 2B-adrenergic receptor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Loury,et al.  Assessment of imiloxan as a selective α2B‐adrenoceptor antagonist , 1990 .

[9]  M. Spedding,et al.  Heterogeneity of α2‐adrenoceptors in rat cortex but not human platelets can be defined by 8‐OH‐DPAT, RU 24969 and methysergide , 1990, British journal of pharmacology.

[10]  J. Wikberg,et al.  Functional supersensitivity of antinociceptive spinal cord alpha 2-adrenoceptors, induced by depletion of endogenous noradrenaline, is associated with an enhanced sensitivity for guanine nucleotide regulation of 3H-clonidine binding. , 1990, Acta Pharmacologica et Toxicologica.

[11]  M. Berlan,et al.  New tools for human fat cell alpha-2A adrenoceptor characterization. Identification on membranes and on intact cells using the new antagonist [3H]RX821002. , 1990, The Journal of pharmacology and experimental therapeutics.

[12]  D. Langin,et al.  Imidazolinic radioligands for the identification of hamster adipocyte α2-adrenoceptors , 1989 .

[13]  D. Loury,et al.  Differences between the α2‐adrenoceptor in rat submaxillary gland and the α2A‐ and α2B‐adrenoceptor subtypes , 1989 .

[14]  M. Cawthorne,et al.  Novel α2-adrenoceptor antagonists show selectivity for α2A- and α2B-adrenoceptor subtypes , 1989 .

[15]  D. Langin,et al.  [3H]RX821002: a new tool for the identification of α2A-adrenoceptors , 1989 .

[16]  J. De Keyser,et al.  High affinity binding of 3H rauwolscine and 3H RX781094 to alpha 2 adrenergic receptors and non-stereoselective sites in human and rabbit brain cortex membranes. , 1989, Biochemical pharmacology.

[17]  J. Wikberg.  High affinity binding of idazoxan to a non-catecholaminergic binding site in the central nervous system: description of a putative idazoxan-receptor. , 1989, Pharmacology & toxicology.

[18]  D. Bylund.  Sub types of α2-adrenoceptors: Pharmacological and molecular biological evidence converg , 1988 .

[19]  M. Caron,et al.  Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Bylund,et al.  Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. , 1988, The Journal of pharmacology and experimental therapeutics.

[21]  M. Wood,et al.  Heterogeneous 3H-rauwolscine binding sites in rat cortex: two alpha 2-adrenoceptor subtypes or an additional non-adrenergic interaction? , 1988, Life sciences.

[22]  M. Caron,et al.  Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. , 1987, Science.

[23]  J. Nunnari,et al.  Regulation of porcine brain alpha 2-adrenergic receptors by Na+,H+ and inhibitors of Na+/H+ exchange. , 1987, The Journal of biological chemistry.

[24]  T. Archer,et al.  Antinociceptive Effects and Spinal Cord Tissue Concentrations after Intrathecal Injection of Guanfacine or Clonidine into Rats , 1987, Anesthesia and analgesia.

[25]  D. Bylund,et al.  Alpha-2 adrenergic receptor subtypes indicated by [3H]yohimbine binding in human brain. , 1986, Life sciences.

[26]  J. T. Turner,et al.  Alpha 2-adrenergic receptors in the human cell line, HT29. Characterization with the full agonist radioligand [3H]UK-14,304 and inhibition of adenylate cyclase. , 1985, Molecular pharmacology.

[27]  M. Raiteri,et al.  Alpha 2-adrenoceptors in rat hypothalamus and cerebral cortex: functional evidence for pharmacologically distinct subpopulations. , 1985, European journal of pharmacology.

[28]  J. Wikberg,et al.  Noradrenaline depletion increases noradrenaline-induced antinociception in mice , 1985, Neuroscience Letters.

[29]  R. Summers,et al.  [3H]‐rauwolscine binding to α2‐adrenoceptors in the mammalian kidney: apparent receptor heterogeneity between species , 1985, British journal of pharmacology.

[30]  D. Bylund.  Heterogeneity of alpha-2 adrenergic receptors , 1985, Pharmacology Biochemistry and Behavior.

[31]  T. Yaksh.  Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing , 1985, Pharmacology Biochemistry and Behavior.

[32]  S. Savage,et al.  Intrathecal morphine tolerance: use of intrathecal clonidine, DADLE, and intraventricular morphine. , 1985, Anesthesiology.

[33]  D. Barnett,et al.  α-Adrenoceptor-effector coupling: affinity states or heterogeneity of the α2-adrenoceptor? , 1985 .

[34]  T. Gordh,et al.  EPIDURAL CLONIDINE PRODUCES ANALGESIA , 1984, The Lancet.

[35]  D. U'prichard.  Biochemical Characteristics and Regulation of Brain α2‐Adrenoceptors a , 1984 .

[36]  P. Insel,et al.  Characterization of alpha-adrenergic receptor subtypes in the rat renal cortex. Differential regulation of alpha 1- and alpha 2-adrenergic receptors by guanyl nucleotides and Na. , 1982, Molecular pharmacology.

[37]  D. Barnett,et al.  [3H]Rauwolscine and [3H]yohimbine binding to rat cerebral and human platelet membranes: possible heterogeneity of alpha 2-adrenoceptors. , 1982, European journal of pharmacology.

[38]  R. Lefkowitz,et al.  Agonist interactions with alpha-adrenergic receptors. , 1982, Journal of cardiovascular pharmacology.

[39]  T. Yaksh,et al.  Functional aspects of bulbospinal monoaminergic projections in modulating processing of somatosensory information. , 1981, Federation proceedings.

[40]  R. Lefkowitz,et al.  Agonist versus antagonist binding to alpha-adrenergic receptors. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Lefkowitz,et al.  Heterogeneity of radioligand binding to alpha-adrenergic receptors. Analysis of guanine nucleotide regulation of agonist binding in relation to receptor subtypes. , 1980, The Journal of biological chemistry.

[42]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.